US FDA approves injectable version of Roche's multiple sclerosis therapy
Sept 13 (Reuters) -The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis.
The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.
The therapy is already approved as an IV infusion for multiple sclerosis under the brand name Ocrevus, which is given twice a year. The subcutaneous version is a 10-minute injection also given twice a year.
Ocrevus is used to treat patients with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis.
Multiple sclerosis is a condition that occurs when the immune system attacks the brain and spinal cord. The company estimates that the disease affects more than 2.9 million people worldwide.
The approval was based on data from a late-stage study that showed no significant difference in Ocrevus levels in the blood when administered subcutaneously.
The subcutaneous formulation, which received marketing authorization from the European Commission in June, combines Ocrevus with Halozyme Therapeutics' HALO.O drug delivery technology, which allows the therapy to be rapidly dispersed and absorbed into the bloodstream.
Ocrevus is a monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to nerve cell damage.
More than 350,000 people with multiple sclerosis have been treated with Ocrevus IV globally, according to Roche. The IV formulation of Ocrevus recorded sales of 6.38 billion Swiss francs ($7.52 billion) in 2023.
Other approved treatments for RMS include Novartis' NOVN.S Kesimpta, given as a monthly injection, and Biogen's BIIB.O Tysabri, administered as an IV infusion every four weeks.
($1 = 0.8481 Swiss francs)
Reporting by Sneha S K, Sruthi Narasimha Chari and Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar and Vijay Kishore
āĻ¸āĻŽā§āĻĒāĻ°ā§āĻāĻŋāĻ¤ āĻ ā§āĻ¯āĻžāĻ¸ā§āĻ
āĻ¸āĻ°ā§āĻŦāĻļā§āĻˇ āĻāĻŦāĻ°
āĻĻāĻžāĻŦāĻŋāĻ¤ā§āĻ¯āĻžāĻ: XM Group āĻāĻ° āĻ¸āĻ¤ā§āĻ¤ā§āĻŦāĻžāĻā§āĻ˛ā§ āĻļā§āĻ§ā§āĻŽāĻžāĻ¤ā§āĻ° āĻāĻžāĻ°ā§āĻ¯āĻāĻ° āĻ¸ā§āĻŦāĻž āĻĒā§āĻ°āĻĻāĻžāĻ¨ āĻāĻ°ā§ āĻāĻŦāĻ āĻāĻŽāĻžāĻĻā§āĻ° āĻ āĻ¨āĻ˛āĻžāĻāĻ¨ āĻā§āĻ°ā§āĻĄāĻŋāĻ āĻ¸ā§āĻŦāĻŋāĻ§āĻž āĻā§āĻ˛ā§ āĻāĻĒāĻā§āĻ āĻāĻ°āĻ¤ā§ āĻĻā§ā§, āĻ¸ā§āĻāĻ¸āĻžāĻĨā§ āĻāĻāĻāĻ¨ āĻŦā§āĻ¯āĻā§āĻ¤āĻŋāĻā§ āĻāĻ¯āĻŧā§āĻŦāĻ¸āĻžāĻāĻā§ āĻŦāĻž āĻāĻ° āĻŽāĻžāĻ§ā§āĻ¯āĻŽā§ āĻāĻĒāĻ˛āĻŦā§āĻ§ āĻŦāĻŋāĻˇāĻ¯āĻŧāĻŦāĻ¸ā§āĻ¤ā§ āĻĻā§āĻāĻ¤ā§ āĻāĻŦāĻ/āĻ āĻĨāĻŦāĻž āĻŦā§āĻ¯āĻŦāĻšāĻžāĻ° āĻāĻ°āĻžāĻ° āĻ āĻ¨ā§āĻŽāĻ¤āĻŋ āĻĻā§ā§ āĻ¤āĻŦā§ āĻāĻāĻŋ āĻā§āĻ¨ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ āĻŦāĻž āĻĒā§āĻ°āĻ¸āĻžāĻ°āĻŋāĻ¤ āĻāĻ°āĻžāĻ° āĻāĻĻā§āĻĻā§āĻļā§āĻ¯ā§ āĻ¨āĻ¯āĻŧ āĻŦāĻž āĻāĻŽāĻ¨ āĻā§āĻ¨ āĻāĻžāĻ°āĻŖā§āĻ āĻ¨āĻ¯āĻŧāĨ¤ āĻāĻ āĻ§āĻ°āĻ¨ā§āĻ° āĻĒā§āĻ°āĻŦā§āĻļ āĻāĻŦāĻ āĻŦā§āĻ¯āĻŦāĻšāĻžāĻ° āĻ¸āĻŦāĻ¸āĻŽāĻ¯āĻŧ āĻāĻŋāĻā§ āĻŦāĻŋāĻˇā§ā§āĻ° āĻ¸āĻžāĻĨā§ āĻā§āĻŋāĻ¤: (i) āĻļāĻ°ā§āĻ¤āĻžāĻŦāĻ˛ā§; (ii) āĻā§āĻāĻāĻŋ āĻ¸āĻ¤āĻ°ā§āĻāĻ¤āĻž; āĻāĻŦāĻ (iii) āĻ¸āĻŽā§āĻĒā§āĻ°ā§āĻŖ āĻĻāĻžāĻŦāĻŋāĻ¤ā§āĻ¯āĻžāĻāĨ¤ āĻāĻ āĻ§āĻ°āĻ¨ā§āĻ° āĻŦāĻŋāĻˇāĻ¯āĻŧāĻŦāĻ¸ā§āĻ¤ā§ āĻ¤āĻžāĻ āĻ¸āĻžāĻ§āĻžāĻ°āĻŖ āĻ¤āĻĨā§āĻ¯ āĻšāĻŋāĻ¸ā§āĻŦā§ āĻāĻžāĻĄāĻŧāĻž āĻāĻ° āĻ āĻ¨ā§āĻ¯ āĻā§āĻ¨ āĻāĻĻā§āĻĻā§āĻļā§āĻ¯ā§ āĻĒā§āĻ°āĻĻāĻžāĻ¨ āĻāĻ°āĻž āĻšāĻ¯āĻŧ āĻ¨āĻžāĨ¤ āĻ āĻ¨ā§āĻā§āĻ°āĻš āĻāĻ°ā§ āĻŦāĻŋāĻļā§āĻˇāĻāĻžāĻŦā§ āĻ¸āĻā§āĻ¤āĻ¨ āĻĨāĻžāĻā§āĻ¨ āĻ¯ā§, āĻāĻŽāĻžāĻĻā§āĻ° āĻ āĻ¨āĻ˛āĻžāĻāĻ¨ āĻā§āĻ°ā§āĻĄāĻŋāĻ āĻ¸ā§āĻŦāĻŋāĻ§āĻžāĻ° āĻŦāĻŋāĻˇāĻ¯āĻŧāĻŦāĻ¸ā§āĻ¤ā§āĻā§ā§āĻ˛ā§ āĻāĻ°ā§āĻĨāĻŋāĻ āĻŦāĻžāĻāĻžāĻ°ā§ āĻā§āĻ¨ā§ āĻ˛ā§āĻ¨āĻĻā§āĻ¨ āĻāĻ°āĻžāĻ° āĻāĻ¨ā§āĻ¯ āĻ āĻ¨ā§āĻ°ā§āĻ§ āĻŦāĻž āĻĒā§āĻ°āĻ¸ā§āĻ¤āĻžāĻŦ āĻ¨āĻ¯āĻŧāĨ¤ āĻāĻžāĻ°āĻŖ āĻ¯ā§āĻā§āĻ¨ā§ āĻāĻ°ā§āĻĨāĻŋāĻ āĻŦāĻžāĻāĻžāĻ°ā§ āĻā§āĻ°ā§āĻĄāĻŋāĻ āĻāĻ°āĻ˛ā§ āĻāĻĒāĻ¨āĻžāĻ° āĻŽā§āĻ˛āĻ§āĻ¨ā§āĻ° āĻ¸āĻžāĻĨā§ āĻāĻāĻāĻŋ āĻāĻ˛ā§āĻ˛ā§āĻāĻ¯ā§āĻā§āĻ¯ āĻā§āĻāĻāĻŋ āĻāĻĄāĻŧāĻŋāĻ¤ āĻĨāĻžāĻāĻŦā§āĨ¤
āĻāĻŽāĻžāĻĻā§āĻ° āĻ āĻ¨āĻ˛āĻžāĻāĻ¨ āĻā§āĻ°ā§āĻĄāĻŋāĻ āĻ¸ā§āĻŦāĻŋāĻ§āĻžāĻ¯āĻŧ āĻĒā§āĻ°āĻāĻžāĻļāĻŋāĻ¤ āĻ¸āĻāĻ˛ āĻŦāĻŋāĻˇā§āĻŦāĻ¸ā§āĻ¤ā§ āĻļā§āĻ§ā§āĻŽāĻžāĻ¤ā§āĻ° āĻļāĻŋāĻā§āĻˇāĻžāĻāĻ¤/āĻ¤āĻĨā§āĻ¯āĻŽā§āĻ˛āĻ āĻāĻĻā§āĻĻā§āĻļā§āĻ¯ā§ āĻ¤ā§āĻ°āĻŋ āĻāĻ°āĻž āĻšāĻ¯āĻŧā§āĻ āĻāĻŦāĻ āĻāĻ¤ā§ āĻāĻ°ā§āĻĨāĻŋāĻ, āĻŦāĻŋāĻ¨āĻŋāĻ¯āĻŧā§āĻ āĻāĻ° āĻŦāĻž āĻā§āĻ°ā§āĻĄāĻŋāĻ āĻĒāĻ°āĻžāĻŽāĻ°ā§āĻļ āĻāĻŦāĻ āĻ¸ā§āĻĒāĻžāĻ°āĻŋāĻļ āĻ§āĻžāĻ°āĻŖ āĻāĻ°āĻž āĻāĻāĻŋāĻ¤ āĻ¨āĻ¯āĻŧ - āĻāĻŽāĻžāĻĻā§āĻ° āĻā§āĻ°ā§āĻĄāĻŋāĻ āĻŽā§āĻ˛ā§āĻ¯ā§āĻ° āĻāĻāĻāĻŋ āĻ°ā§āĻāĻ°ā§āĻĄ; āĻ āĻĨāĻŦāĻž āĻā§āĻ¨ā§ āĻāĻ°ā§āĻĨāĻŋāĻ āĻāĻĒāĻāĻ°āĻŖā§ āĻ˛ā§āĻ¨āĻĻā§āĻ¨ā§āĻ° āĻĒā§āĻ°āĻ¸ā§āĻ¤āĻžāĻŦ, āĻŦāĻž āĻ āĻ¨ā§āĻ°ā§āĻ§; āĻ āĻĨāĻŦāĻž āĻāĻĒāĻ¨āĻžāĻ° āĻāĻžāĻā§ āĻ āĻ¯āĻžāĻāĻŋāĻ¤ āĻāĻ°ā§āĻĨāĻŋāĻ āĻĒā§āĻ°āĻāĻžāĻ° āĻšāĻŋāĻ¸ā§āĻŦā§ āĻāĻāĻŋāĻā§ āĻ§āĻžāĻ°āĻŖ āĻāĻ°āĻž āĻāĻāĻŋāĻ¤ āĻ¨āĻ¯āĻŧāĨ¤
āĻā§āĻ¨ āĻ¤ā§āĻ¤ā§āĻ¯āĻŧ āĻĒāĻā§āĻˇā§āĻ° āĻŦāĻŋāĻˇā§āĻŦāĻ¸ā§āĻ¤ā§, āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ XM āĻĻā§āĻŦāĻžāĻ°āĻž āĻĒā§āĻ°āĻ¸ā§āĻ¤ā§āĻ¤ āĻŦāĻŋāĻˇā§ āĻŦāĻ¸ā§āĻ¤ā§ āĻ¯ā§āĻŽāĻ¨ āĻŽāĻ¤āĻžāĻŽāĻ¤, āĻ¸āĻāĻŦāĻžāĻĻ, āĻāĻŦā§āĻˇāĻŖāĻž, āĻŦāĻŋāĻļā§āĻ˛ā§āĻˇāĻŖ, āĻĻāĻžāĻŽ, āĻ āĻ¨ā§āĻ¯āĻžāĻ¨ā§āĻ¯ āĻ¤āĻĨā§āĻ¯ āĻŦāĻž āĻāĻ āĻāĻ¯āĻŧā§āĻŦāĻ¸āĻžāĻāĻā§ āĻĨāĻžāĻāĻž āĻ¤ā§āĻ¤ā§āĻ¯āĻŧ āĻĒāĻā§āĻˇā§āĻ° āĻ¸āĻžāĻāĻā§āĻ° āĻ˛āĻŋāĻāĻ āĻā§āĻ˛ā§ "āĻ¯ā§āĻŽāĻ¨-āĻ°āĻ¯āĻŧā§āĻā§" āĻāĻŋāĻ¤ā§āĻ¤āĻŋāĻ¤ā§ āĻ¸āĻ°āĻŦāĻ°āĻžāĻš āĻāĻ°āĻž āĻšāĻ¯āĻŧ āĻ¸āĻžāĻ§āĻžāĻ°āĻŖ āĻŽāĻžāĻ°ā§āĻā§āĻā§āĻ° āĻāĻžāĻˇā§āĻ¯ āĻšāĻŋāĻ¸ā§āĻŦā§ āĻāĻŦāĻ āĻŦāĻŋāĻ¨āĻŋāĻ¯āĻŧā§āĻā§āĻ° āĻĒāĻ°āĻžāĻŽāĻ°ā§āĻļ āĻāĻ āĻ¨ āĻāĻ°āĻŦā§āĻ¨ āĻ¨āĻžāĨ¤ āĻ¯ā§āĻā§āĻ¨ā§ āĻŦāĻŋāĻˇāĻ¯āĻŧāĻŦāĻ¸ā§āĻ¤ā§āĻā§ āĻŦāĻŋāĻ¨āĻŋāĻ¯āĻŧā§āĻ āĻāĻŦā§āĻˇāĻŖāĻž āĻšāĻŋāĻ¸ā§āĻŦā§ āĻŦā§āĻāĻžāĻ¨ā§ āĻšāĻ˛ā§, āĻāĻĒāĻ¨āĻžāĻā§ āĻ āĻŦāĻļā§āĻ¯āĻ āĻŽāĻ¨ā§ āĻ°āĻžāĻāĻ¤ā§ āĻšāĻŦā§ āĻāĻŦāĻ āĻ¸ā§āĻŦā§āĻāĻžāĻ° āĻāĻ°āĻ¤ā§ āĻšāĻŦā§ āĻ¯ā§ āĻŦāĻŋāĻˇāĻ¯āĻŧāĻŦāĻ¸ā§āĻ¤ā§āĻāĻŋ āĻŦāĻŋāĻ¨āĻŋāĻ¯āĻŧā§āĻ āĻāĻŦā§āĻˇāĻŖāĻžāĻ° āĻ¸ā§āĻŦāĻžāĻ§ā§āĻ¨āĻ¤āĻžāĻ° āĻĒā§āĻ°āĻāĻžāĻ°ā§āĻ° āĻāĻ¨ā§āĻ¯ āĻĄāĻŋāĻāĻžāĻāĻ¨ āĻāĻ°āĻž āĻāĻāĻ¨āĻŋ āĻĒā§āĻ°āĻ¯āĻŧā§āĻāĻ¨ā§āĻ¯āĻŧāĻ¤āĻž āĻ āĻ¨ā§āĻ¸āĻžāĻ°ā§ āĻ¤ā§āĻ°āĻŋ āĻāĻ°āĻž āĻšāĻ¯āĻŧāĻ¨āĻŋ āĻāĻŦāĻ āĻāĻāĻŋ āĻŦāĻŋāĻŦā§āĻāĻ¨āĻž āĻāĻ°āĻž āĻšāĻŦā§ āĻ¨āĻž āĻĒā§āĻ°āĻžāĻ¸āĻā§āĻāĻŋāĻ āĻāĻāĻ¨ āĻ āĻĒā§āĻ°āĻŦāĻŋāĻ§āĻžāĻ¨ā§āĻ° āĻ āĻ§ā§āĻ¨ā§ āĻŦāĻŋāĻĒāĻŖāĻ¨ āĻ¯ā§āĻāĻžāĻ¯ā§āĻ āĻšāĻŋāĻ¸ā§āĻŦā§āĨ¤ āĻ āĻ¨ā§āĻā§āĻ°āĻš āĻāĻ°ā§ āĻ¨āĻŋāĻļā§āĻāĻŋāĻ¤ āĻāĻ°ā§āĻ¨ āĻ¯ā§ āĻāĻĒāĻ¨āĻŋ āĻ -āĻ¸ā§āĻŦāĻžāĻ§ā§āĻ¨ āĻŦāĻŋāĻ¨āĻŋāĻ¯āĻŧā§āĻ āĻ¸āĻāĻā§āĻ°āĻžāĻ¨ā§āĻ¤ āĻāĻŽāĻžāĻĻā§āĻ° āĻŦāĻŋāĻā§āĻāĻĒā§āĻ¤āĻŋ āĻĒāĻĄāĻŧā§āĻā§āĻ¨ āĻāĻŦāĻ āĻŦā§āĻā§āĻā§āĻ¨āĨ¤ āĻĒā§āĻ°ā§āĻŦā§āĻā§āĻ¤ āĻ¤āĻĨā§āĻ¯ āĻ¸āĻŽā§āĻĒāĻ°ā§āĻāĻŋāĻ¤ āĻāĻŦā§āĻˇāĻŖāĻž āĻāĻŦāĻ āĻā§āĻāĻāĻŋ āĻ¸āĻ¤āĻ°ā§āĻāĻ¤āĻž, āĻ¯āĻž āĻāĻāĻžāĻ¨ āĻĨā§āĻā§ āĻĒā§āĻ°āĻŦā§āĻļ āĻāĻ°āĻž āĻ¯ā§āĻ¤ā§ āĻĒāĻžāĻ°ā§āĨ¤